SNO 2018: Temozolomide-Based Chemoradiotherapy Prolongs Survival Long Term in High-Risk, Low-Grade Gliomas
Survival is 9 years with chemoradiotherapy vs 5 years with radiation alone.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.